Status:
TERMINATED
Low Energy Surface Waves for Neurogenic Bladder Patients With Indwelling Catheters
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Neurogenic Bladder
Urinary Tract Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The Uroshield device is a commercially available device with two parts: a disposable actuator which attaches to the external portion of the catheter and a portable battery. The device sends out low-fr...
Eligibility Criteria
Inclusion
- \>18 years of age
- Spinal cord injury (\>1 year), multiple sclerosis (\>1 year), spina bifida, parkinsons (\>1 year)
- Indwelling catheter (urethral or suprapubic) for \>3 months, and used as primary bladder management mechanism
- \>1 urinary tract infection in the last 12 months
Exclusion
- Intravesical botox in the last 6 months
- Chronic antibiotic suppressive therapy
- Active symptomatic UTI on day of randomization
- Unable to understand written and spoken English
- Prior/current utilization of the Uroshield device
Key Trial Info
Start Date :
January 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03785262
Start Date
January 30 2019
End Date
December 30 2023
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Josephs Hospital
London, Ontario, Canada, N6A 4V2